ATE304353T1 - Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff - Google Patents

Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff

Info

Publication number
ATE304353T1
ATE304353T1 AT02745358T AT02745358T ATE304353T1 AT E304353 T1 ATE304353 T1 AT E304353T1 AT 02745358 T AT02745358 T AT 02745358T AT 02745358 T AT02745358 T AT 02745358T AT E304353 T1 ATE304353 T1 AT E304353T1
Authority
AT
Austria
Prior art keywords
inhibitor
combination containing
antiepileptic
active
antiepileptic active
Prior art date
Application number
AT02745358T
Other languages
English (en)
Inventor
Wolfgang Loescher
Heidrun Potschka
Markus Schmutz
Original Assignee
Novartis Pharma Gmbh
Wolfgang Loescher
Heidrun Potschka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Wolfgang Loescher, Heidrun Potschka filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE304353T1 publication Critical patent/ATE304353T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
AT02745358T 2001-06-05 2002-06-04 Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff ATE304353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113663.9A GB0113663D0 (en) 2001-06-05 2001-06-05 Use of organic compounds
PCT/EP2002/006140 WO2002098418A1 (en) 2001-06-05 2002-06-04 Combination comprising a p-gp inhibitor and an anti-epileptic drug

Publications (1)

Publication Number Publication Date
ATE304353T1 true ATE304353T1 (de) 2005-09-15

Family

ID=9915953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745358T ATE304353T1 (de) 2001-06-05 2002-06-04 Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff

Country Status (11)

Country Link
US (2) US20040180816A1 (de)
EP (1) EP1399157B1 (de)
JP (1) JP2004536076A (de)
CN (1) CN1617719A (de)
AT (1) ATE304353T1 (de)
BR (1) BR0209648A (de)
CA (1) CA2446160A1 (de)
DE (1) DE60206169T2 (de)
ES (1) ES2247352T3 (de)
GB (1) GB0113663D0 (de)
WO (1) WO2002098418A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
AR050043A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US20100041691A1 (en) * 2006-09-12 2010-02-18 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296122B1 (de) * 1987-06-17 1993-09-29 Sandoz Ag Cyclosporine und deren Benutzung als Arzneimittel
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
JPH08127541A (ja) * 1994-10-31 1996-05-21 Chugai Pharmaceut Co Ltd 新規制癌剤
GB9721352D0 (en) * 1997-10-08 1997-12-10 Medinnova Sf Resistance modifying agent

Also Published As

Publication number Publication date
EP1399157A1 (de) 2004-03-24
DE60206169T2 (de) 2006-06-08
EP1399157B1 (de) 2005-09-14
US20070142266A1 (en) 2007-06-21
JP2004536076A (ja) 2004-12-02
CN1617719A (zh) 2005-05-18
ES2247352T3 (es) 2006-03-01
DE60206169D1 (de) 2005-10-20
HK1064278A1 (en) 2005-01-28
US20040180816A1 (en) 2004-09-16
WO2002098418A1 (en) 2002-12-12
CA2446160A1 (en) 2002-12-12
BR0209648A (pt) 2004-07-06
GB0113663D0 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
NO20045323L (no) Antistoffer
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
MA31822B1 (fr) Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
IS6997A (is) Lyfjafræðilega virkir úridín esterar
TR200003808T2 (tr) Bir cox-2 inhibitörü içeren farmasötik kombinasyon
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
GB0012362D0 (en) Chemical compounds
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
BR0210139A (pt) Composições farmacêuticas
ATE304353T1 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
WO2003106381A3 (en) Human adam-10 inhibitors
MA30921B1 (fr) Formes cristallines de l'aliskiren (hemifumarate)
ATE506959T1 (de) Verwendung von il-18 inhibitoren
EP1461313A4 (de) Inhibitoren von humanem adam-10
BR0315139A (pt) Agentes antibacterianos de tetraidroquinolina tricìclica
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
MXPA02010458A (es) Peptido modulador del receptor de trombopoyetina.
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
MA27102A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
PT1368016E (pt) Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac
PL368737A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399157

Country of ref document: EP

REN Ceased due to non-payment of the annual fee